September 6, 2024
Argenica Therapeutics (ASX:AGN) pioneers breakthroughs in neuroprotection with ARG-007
Argenica Therapeutics is advancing its novel neuroprotective drug ARG-007 through a promising Phase 2 trial, with no adverse events reported and potential applications in multiple neurological conditions.
